Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (FUDANZHANGJIANG) has signed a structured deposit product agreement with Bank of China, committing RMB150.00 million of temporarily idle A-share proceeds to a low-risk, principal-guaranteed instrument that offers floating returns.
Key transaction terms • Product: “RMB Structured Deposit of Bank of China” (principal-guaranteed, floating return). • Tenor: 89 days, effective 2 April 2026. • Expected annualised return: 0.35%–1.57%, determined by the performance of the EUR/USD central parity spot rate on Bloomberg (BFIX). – If the rate during 3 April–25 June 2026 is ever not lower than the observation level (benchmark +0.0515), the return is 0.35%. – If consistently below that level, the return rises to 1.57%. • Early termination: Not available to the Company; Bank of China retains termination rights under force majeure or public-interest considerations. • Risk rating: Low, per Bank of China assessment.
Regulatory position Applicable percentage ratios under Hong Kong Listing Rule 14.07 exceed 5% but are below 25%, classifying the deal as a disclosable transaction. Hence, it requires public reporting and announcement but no shareholder approval.
Strategic rationale Deploying idle IPO proceeds into a short-tenor, capital-protected instrument is intended to enhance overall returns while safeguarding liquidity—consistent with the Group’s treasury objectives. The board, including independent non-executive directors, deems the terms fair, reasonable and aligned with shareholder interests.
Counterparties • FUDANZHANGJIANG: PRC-based biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market. • Bank of China: PRC state-owned commercial bank listed in Shanghai and Hong Kong; confirmed as an independent third party to the Company.
Directors as of 2 April 2026: Zhao Da Jun (Chairman & Executive Director), Xue Yan (Executive Director), Shen Bo and Yu Xiao Yang (Non-executive Directors), Wang Hong Guang, Lam Siu Wing, Xu Pei Long (Independent Non-executive Directors), and Qu Ya Nan (Employee Director).